Biocon Ltd

Biocon Ltd gained for a fifth straight session today. The stock is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.33% on the day, quoting at 23767.5. The Sensex is at 75657.84, up 0.34%. Biocon Ltd has gained around 22.75% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.77% in last one month and is currently quoting at 24551.05, up 0.44% on the day. The volume in the stock stood at 56.13 lakh shares today, compared to the daily average of 46.75 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 431.7, up 2.65% on the day. Biocon Ltd is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma index.The PE of the stock is 285.14 based on TTM earnings ending March 26.Powered by Capital Market - Live

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 417.35, up 3.7% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 23468.45. The Sensex is at 74886.66, up 0.44%. Biocon Ltd has added around 19.12% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has added around 6.63% in last one month and is currently quoting at 23840.9, up 0.34% on the day. The volume in the stock stood at 68.88 lakh shares today, compared to the daily average of 40.85 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 419.55, up 3.75% on the day. Biocon Ltd is up 23.4% in last one year as compared to a 4.86% fall in NIFTY and a 11.37% fall in the Nifty Pharma index.The PE of the stock is 273.57 based on TTM earnings ending March 26.Powered by Capital Market - Live

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 386.7, up 1.16% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 24164.3. The Sensex is at 77254.26, down 0.76%. Biocon Ltd has gained around 11.86% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.02% in last one month and is currently quoting at 24135.5, down 0.02% on the day. The volume in the stock stood at 42.2 lakh shares today, compared to the daily average of 29.37 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 385.55, up 0.26% on the day. Biocon Ltd is up 17.22% in last one year as compared to a 0.65% jump in NIFTY and a 14.52% jump in the Nifty Pharma index.The PE of the stock is 318.83 based on TTM earnings ending December 25.Powered by Capital Market - Live

Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review. EBIDTA fell by 3.77% to Rs 1,073 crore while EBIDTA margin declined by 200 basis points YoY to 23% in Q4 FY26. Profit before tax in Q4 FY26 stood at Rs 248 crore, down by 49.2% from Rs 487 crore in Q4 FY25. For FY26, the company has recorded consolidated net profit and revenue from operations of Rs 386 crore (down 61.9% YoY) and Rs 16,927 crore (up 10.9% YoY), respectively. Kiran Mazumdar-Shaw, executive chairperson, Biocon, said: 'Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration. We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The scrip advanced 2.43% to currently trade at Rs 391.90 on the BSE. Powered by Capital Market - Live

Biocon announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.

Net profit of Biocon declined 63.45% to Rs 125.90 crore in the quarter ended March 2026 as against Rs 344.50 crore during the previous quarter ended March 2025. Sales rose 2.90% to Rs 4484.30 crore in the quarter ended March 2026 as against Rs 4358.10 crore during the previous quarter ended March 2025. For the full year,net profit declined 61.95% to Rs 385.60 crore in the year ended March 2026 as against Rs 1013.30 crore during the previous year ended March 2025. Sales rose 11.48% to Rs 16779.90 crore in the year ended March 2026 as against Rs 15052.20 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales4484.304358.10 3 16779.9015052.20 11 OPM %22.7524.74 -20.5921.04 - PBDT841.30902.70 -7 2807.503477.10 -19 PBT327.90466.40 -30 850.801790.10 -52 NP125.90344.50 -63 385.601013.30 -62 Powered by Capital Market - Live

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 380.1, up 3.22% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 24018.3. The Sensex is at 76839.15, down 0.23%. Biocon Ltd has risen around 11.78% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 10.1% in last one month and is currently quoting at 23568.95, up 2.16% on the day. The volume in the stock stood at 43.36 lakh shares today, compared to the daily average of 34.91 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 381.8, up 3.04% on the day. Biocon Ltd is up 9.7% in last one year as compared to a 1.62% drop in NIFTY and a 12.19% drop in the Nifty Pharma index.The PE of the stock is 307.42 based on TTM earnings ending December 25.Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 362.1, up 0.85% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.77% on the day, quoting at 24552.55. The Sensex is at 79171.6, up 0.83%. Biocon Ltd has slipped around 1.38% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.88% in last one month and is currently quoting at 22456.75, up 0.05% on the day. The volume in the stock stood at 15.64 lakh shares today, compared to the daily average of 40.6 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 361.85, up 0.88% on the day. Biocon Ltd is up 8.48% in last one year as compared to a 1.59% jump in NIFTY and a 4.81% jump in the Nifty Pharma index.The PE of the stock is 298.75 based on TTM earnings ending December 25.

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, demonstrating that BOSAYA and VEVZUO are highly similar to PROLIA and XGEVA, respectively, with no clinically meaningful differences in quality, safety, or efficacy. Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer. Shreehas Tambe, CEO & managing director, Biocon, said: 'Health Canada's approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets. This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.